Streetbeat News

Revenues

NBIX

VYGR

Voyager Therapeutics and Neurocrine Biosciences have selected a development candidate for Friedreich's Ataxia, triggering a $5M milestone payment to Voyager. Voyager is set to receive this payment in Q1 2024 and is eligible for future payments based on program advancement.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:15 pm

NTRA

The Centers For Medicare & Medicaid Services (CMS) has expanded coverage for Natera's Signatera Molecular Residual Disease Test to include ovarian cancer and neoadjuvant breast cancer. This decision broadens the potential patient base for Natera's diagnostic test, potentially increasing its usage and revenue from these additional cancer types.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:11 pm

FIS

Fidelity National Info (FIS) reported Q4 earnings of $0.94 per share, meeting analyst estimates. However, its quarterly sales of $2.51 billion fell short of the $2.53 billion estimate, marking a 32.42% decrease from the previous year's $3.71 billion.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:06 pm

TRNR

Interactive Strength Inc. (TRNR) has signed an exclusive worldwide distribution agreement with WOODWAY USA Inc. for the sale and distribution of its CLMBR product. The deal includes an initial order of 2,150 units from WOODWAY, expected to generate over $7 million in net revenue for TRNR. This agreement supports TRNR's revenue guidance of $15 million to $20 million for 2024.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:06 pm

FIS

FIS provided its Q1 adjusted EPS guidance in the range of $0.94-$0.97, slightly below the $0.95 estimate. Revenue guidance for Q1 is set at $2.43B-$2.455B, marginally below the $2.46B estimate. For FY24, FIS forecasts an adjusted EPS of $4.66-$4.76, surpassing the $4.42 estimate, with revenue projections of $10.1B-$10.15B, slightly below the $10.12B estimate.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:05 pm

TGTX

TG Therapeutics, Inc. announced the European launch of BRIUMVI for treating relapsing forms of multiple sclerosis, starting in Germany, with plans for further European expansion. The launch triggers a $12.5M milestone payment to TG Therapeutics from its partner, Neuraxpharm Group.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:03 pm

BCRX

BioCryst Pharmaceuticals forecasts its fiscal year 2024 net revenue for Orladeyo to be between $380M-$400M. The company anticipates operating profit in 2024, with expectations of approaching positive EPS and achieving positive cash flow in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:03 pm

SWN

In the last three months, 8 analysts have provided diverse ratings on Southwestern Energy (NYSE:SWN), with a shift towards a more neutral stance in the last 30 days. The average 12-month price target is $7.39, slightly down by 0.4%. The company faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management, indicating potential difficulties in achieving strong profitability and efficient asset utilization.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 12:02 pm

DV

DoubleVerify Holdings (NYSE:DV) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for DV has been raised to $44.5, indicating a 13.38% increase from the previous target. Analysts from firms like Keybanc, JMP Securities, and Barclays have raised their price targets, reflecting optimism about DV's market performance. The company has shown solid revenue growth of 28.26% as of September 30, 2023, and boasts a high net margin of 9.27%, although its ROE is below industry benchmarks.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 12:01 pm

ROOT

In the latest quarter, 4 analysts provided mixed ratings for Root Inc (NASDAQ:ROOT), with an updated average 12-month price target of $14.75, marking a 43.9% increase from the previous target. Analysts from Keefe, Bruyette & Woods, Citigroup, Wells Fargo, and Cantor Fitzgerald have raised their price targets, reflecting optimism about Root's future performance. Root, a direct-to-consumer auto insurance and mobile technology company, has shown a significant revenue growth rate of 56.45% as of September 30, 2023, but struggles with profitability and debt management.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 12:01 pm